丹参酮ⅡA磺酸钠治疗不稳定型心绞痛的临床应用研究

目的观察丹参酮ⅡA磺酸钠注射液治疗不稳定型心绞痛(UAP)的疗效以及对不稳定型心绞痛血清炎症因子水平的影响。方法将2007年12月～2009年10月间在我院心内科住院治疗的64例UAP患者随机分为治疗组(32例)和对照组(32例),两组均常规给予硝酸酯类、β受体阻滞剂、阿司匹林等药物治疗。治疗组加用丹参酮ⅡA磺酸钠注射液,疗程为14d,观察治疗前后临床症状、EGG及血液流变学等参数变化,比较两组治疗的临床疗效;测定各组患者入院时和治疗后hs-CRP、IL-6的水平。结果加用丹参酮ⅡA磺酸钠注射液干预2周后,治疗组临床症状、EGG及血液流变学参数的改善均优于对照组,两组间比较差异有统计学意义(P0.05);两组血清hs-CRP、IL-6水平及两组治疗后血清hs-CRP、IL-6水平比较差异均有统计学意义(P0.05)。结论在常规治疗基础上加用丹参酮ⅡA磺酸钠可显著降低不稳定型心绞痛患者血清中多种炎症因子水平,并明显改善不稳定型心绞痛患者的临床症状。

Sulfotanshinone Sodium for Unstable Angina Pectoris: A Study of Clinical Application

Objective To observe the clinical effect of Sulfotanshinone sodium injection on unstable angina pectoris（UAP） and serum inflammative factors. Methods Sixty-four cases of UAP admitted to our hospital from Dec.2007 to Oc.2009 were randomly divided into treatment group （32 cases） and the control group （32 cases）. Similar dosage of Nitrates, βblocker and Aspirin were administered as baseline therapy in both groups. Sulfotanshinone sodium injection was added to the treatment group for 7 days. Clinical symptoms, ECG and hamotological viscosity parameters were compared,and serum hs-CRP and IL-6 were monitored before and after Sulfotanshinone sodium intervention. Results The improvement of clinical symptoms,ECG and hematological viscosity in the treatment group was superior to the control group （P〈0.05）, and there was a significant difference in the serum hs-CRP and IL-6 after Sulfotanshinone sodium injection intervention between the two groups （P〈0.05）. Conclusion The regimen of baseline medication combined with Sulfotanshinone sodium can significantly decrease the serum level of hsCRP and IL-6. Meanwhile,the symptoms of UAP are obviously improved.